Daniel Drucker and his pioneering work in obesity and diabetes.
Highlights:
- Drucker emphasizes that impactful research begins by asking questions that truly matter and haven’t yet been answered.
- A single elective course and a great mentor (Dr. Burrow) opened the door to a research career and future breakthroughs.
- His decades-long work on GLP-1 led to therapies for diabetes, obesity, and cardiovascular disease, showing how slow science can yield massive health impact.
- Drucker believes in using science to replace stigma with solutions, especially in conditions like obesity, where treatment now goes beyond blame to real biological help.
- While awards are nice, what drives Drucker is hearing directly from patients whose lives have improved thanks to his research.
“I liked science. I liked English. I liked business,” says Dr. Daniel Drucker, endocrinologist, researcher, and pioneer in obesity and diabetes treatment. Too many interests, he admits. As a young man, he even considered becoming a lawyer. “Honestly, I thought I would,” he says. He was both intrigued and unsettled by the tension between the subjective and the objective. “Maybe I felt insecure and couldn’t navigate the humanities,” he confesses. He remembers the feeling he had in English literature classes. After reading King Lear and submitting a report, he’d hear: “No, that’s not what Shakespeare meant.” The phrase puzzled him. How could anyone know with certainty what Shakespeare intended? And what if there’s more than one answer?
There are scientific laws that govern the rules of chemistry and physics, and to some extent, biology too.
Daniel Drucker
Unlike literature or law, he saw science as a path that offered verifiable answers. That’s why Drucker chose that route. He was drawn to facts, methods, and logic. “There are scientific laws that govern the rules of chemistry and physics, and to some extent, biology too.”
Seeing his father go through economic hardship, he also thought medicine would offer stability. “People like to say they’ve always had a vision, that they always knew what they wanted to do and had a plan,” he says, reflecting on his own journey. Daniel liked school. He liked learning. He liked science and medicine. “I was very lucky,” he states.
In 1976, he enrolled at the University of Toronto, home to the only medical school in Ontario’s capital at the time. It was an era without computers. Everything was done on paper. To select elective courses, you had to visit an office and flip through binders filled with printed course descriptions. He’d sit and read through them for an hour, just like when you had to go to the library to search for information in the 1970s. On one of those visits, he found an elective taught by the new head of the endocrinology department, Dr. Gerard Burrow, a physician recently arrived from Yale. The course seemed interesting. He wasn’t following a plan, just his curiosity.
He definitely enjoyed the blend of research, science, and medicine, and that made it fun and exciting.
Daniel Drucker
He enrolled and found a mentor who believed in science and optimism. “He definitely enjoyed the blend of research, science, and medicine, and that made it fun and exciting,” Drucker says of his role model. Burrow had a rare talent for turning setbacks into opportunities. “You just wanted to spend time with him,” he recalls.
Endocrinology itself also began to intrigue him. “First of all, it’s very simple. Either you have too much hormone or not enough.” Unlike other medical fields, endocrinology allowed a clear understanding of many disorders, and he loved the idea that there were treatments to fix them. “Almost everything that goes wrong in endocrinology, you can fix,” he says.
Drucker worked in Burrow’s lab focusing on thyroid diseases. “I learned how to do research in his lab.” He could run projects and publish papers. “Being able to conduct experiments, get results, and publish” was completely new and thrilling to him. Thanks to his mentor, who arranged interviews in various labs, Drucker eventually moved to Boston in 1984.
They told me I had to work on the glucagon gene, which had just been identified.
Daniel Drucker
He thought he’d continue working on thyroid disease, but upon arriving at Massachusetts General Hospital and joining Dr. Joel Habener’s lab, the thyroid project was wrapping up. So they gave him a new assignment. “They told me I had to work on the glucagon gene, which had just been identified,” he says. His early work explored the actions of glucagon, a hormone that regulates blood sugar. This led to a series of investigations that, although he didn’t know it at the time, would eventually transform metabolic disease treatment globally.
What I really emphasize is to ask a good question.
Daniel Drucker
For Drucker, the most important part of science is asking meaningful questions. “What I really emphasize is to ask a good question.” Significant research always starts with taking time to figure out what’s worth investigating. “If the question is really good, then no matter the answer, we’ll learn something valuable. But if the question is irrelevant, then who cares?” He even has a rule of thumb: if you share your question with 25 colleagues and they all say, “You know what? No one has really answered that, let me know when you figure it out,” then you’re probably on the right track.
That philosophy stayed with him from his earliest lab projects with Burrow, and later at Massachusetts General, where he joined a team studying glucagon-like peptides (GLPs), a group of hormones activated after eating.
Alongside Dr. Habener, he participated in the first studies on GLP-1, a hormone that stimulates insulin secretion, and later on GLP-2, linked to intestinal function. In parallel, scientist Svetlana Mojsov identified the active part of GLP-1, while in Denmark’s capital, Dr. Jens Juul Holst observed that certain intestinal surgeries caused patients to produce more insulin. Over time, these discoveries converged in a collaborative effort that laid the foundation for understanding peptides’ role in metabolism. Though promising, clinical applications took nearly two decades to arrive. “Slowly, it made its way into clinical use, very slowly,” Drucker says.
“Since the 1980s, I’ve been working on the glucagon gene or on glucagon-like peptides,” he explains. The questions he posed about these peptides paved the way for developing GLP-1-based therapies, now used worldwide to treat type 2 diabetes, obesity, and more recently, kidney disease and cardiovascular risk.
Obesity is linked to higher risk of arthritis, liver disease, heart disease, kidney disease, cancer, neurodegenerative diseases…
Daniel Drucker
Today, their potential is also being studied for Alzheimer’s, Parkinson’s, and addiction, though results are mixed and many studies are still ongoing. Among all applications, Drucker gives special weight to obesity treatment. It marks a shift in how we understand the condition, not as purely physical or aesthetic, but as a complex chronic condition with biological, environmental, and social roots. A condition often stigmatized, yet closely linked to increased risk of disease, and where early intervention prevents complications. “Obesity is linked to higher risk of arthritis, liver disease, heart disease, kidney disease, cancer, neurodegenerative diseases…” he explains.
Still, Drucker emphasizes that today’s medical advances allow us to replace judgment and blame with effective treatments. Weight loss is no longer just about willpower. “Many people try everything and still don’t succeed,” he says. “They can look at the skeptics and critics and say, ‘Yes, I wanted to lose weight. I tried… I just needed help.’” GLP-1-based treatments offer that help. They’ve shown “a reduction in heart attacks, strokes, and mortality,” Drucker affirms.
It feels better to talk to someone whose health has improved, because, at the end of the day, a prize is just a prize. But a human life is the most precious thing we can help take care of.
Daniel Drucker
At the same time, what gives his work meaning is knowing it helps people. “I’m a doctor, right? So being able to do science that truly helps people is a tremendous privilege.” Today, many write to him or approach him at conferences to share how his research has changed their lives. “It feels better to talk to someone whose health has improved, because, at the end of the day, a prize is just a prize. But a human life is the most precious thing we can help take care of,” he concludes.
